All publications and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference.
This application relates generally to sterilization of connectors, more particularly connectors used in a medical application, for example during peritoneal dialysis (PD).
Peritoneal dialysis can be used as a treatment for patients with severe chronic kidney disease. Fluid is introduced through a tube in the abdomen and flushed out periodically either while the patients sleeps, in automated peritoneal dialysis or during regular dialysis sessions through the day, as in continuous ambulatory peritoneal dialysis.
As shown in
This is obviously a complicated and time-consuming process that is highly reliant on patient compliance. If a patient fails to adhere to any of the strict steps of the sterilization procedure, he or she faces a greatly increased risk of a serious infection, commonly referred to as peritonitis. This type of internal infection, if not caught early, may lead to sepsis and death of the patient. Typically, peritoneal dialysis (PD) patients experience a 50% chance of infection during the first 12 to 18 months and experience 15% mortality/yr directly related to the infection. In addition to seriously endangering a patient's health, infections in peritoneal dialysis are also very costly to treat. The average total charges from a peritonitis hospital stay are roughly $50,000 dollars and the entire annual cost on the healthcare system is around $1.5 billion. Given that the noncompliance rate for a standard peritoneal dialysis procedure is around 30%, there is a huge need to help reduce the health and financial burdens of infection.
Ultraviolet (UV) disinfection systems are known in the art. U.S. Pat. Nos. 4,882,496; 7,834,328; 4,620,845; 6,461,568 and U.S. Publication Nos. 2005/0013729 and 2007/0274879, the disclosures of which are incorporated by reference herein in their entireties, describe such systems. However, such systems can be cumbersome, making them difficult for a user to use. Additionally, such systems tend to rely on UV disinfection for complete disinfection, which can, in the absence of proper components and connectors, limit the effectiveness of the disinfection.
The novel features of the invention are set forth with particularity in the claims that follow. A better understanding of the features and advantages of the present invention will be obtained by reference to the following detailed description that sets forth illustrative embodiments, in which the principles of the invention are utilized, and the accompanying drawings of which:
Embodiments of the transfer catheter disclosed herein can be used by peritoneal dialysis (PD) patients. The transfer catheter can be attached to the patient's indwelling catheter 4. The transfer catheter can comprise a valve at the end away from the patient's indwelling catheter. During a peritoneal dialysis session, the patient can connect the transfer catheter to the solution set catheter(s). The patient can use the valve on the transfer catheter to flush away any residual fluid within the valve or fluid which may be sequestered by a non UV-transmissive solution set catheter. The connection between the transfer catheter and the solution set catheter, including the valve, can then be sterilized through exposure to UV light. It has been found that flushing the catheter line in combination with UV sterilization can provide more effective disinfection than UV sterilization alone. Features of the transfer catheter, as will be disclosed in more detail hereinafter, can allow for a minimal volume of fluid to be disinfected or exposed to UV light. Minimizing the volume needed to be disinfected allows for the transfer catheter and valve to comprise a small volume kill zone, and can allow for the transfer catheter and valve to comprise a small size and low profile, which can increase patient comfort while wearing the transfer catheter, for example, between dialysis sessions. Additionally, minimizing the volume to be disinfected can allow for less UV light required for disinfection, which can allow for smaller/fewer UV bulbs and power sources, which in turn, can allow for a smaller UV light applicator. Minimizing the size of the UV applicator can increase patient comfort and convenience.
The transfer valve 110 is connected to the tubular body 102 at a first end via a first connector 105 and has a second connector 112 at its second end. The first connector 105 can be for example, a barb connection, as best seen in
Referring now to
The cover 114 can be configured to be UV transparent (e.g., UV-C transparent). UV transparency can allow components underlying the cover 114 (e.g., the connector 112) to be distributed non-sterile and subsequently disinfected by the user. In some embodiments, the cover 114 comprises a UV-transparent material (e.g., cyclic olefin copolymer (COC) (e.g., Topas®)). Other materials are also possible (e.g., Mitsui chemicals TPX). The cover 114 can comprise a smooth outer surface, which can discourage over-torqueing and improve patient comfort while wearing the transfer catheter. The cover 114 can also comprise a smooth end (e.g., hemispherically shaped). This shape can allow the cover 114 to be comfortable to wear against a patient's skin.
Moving to
As mentioned above, the transfer valve 110 comprises a handle 118. The handle can comprise an underlying rigid skeleton 120 (e.g., a rigid plastic skeleton), as shown in
The handle 118 long axis can be configured to align with the tubular body 102 in the closed position, as shown in
In some embodiments, the valve core can be positioned off-axis from the tubular body 102, as described in more detail below. In such embodiments, the handle 118 can be centered on the tubular body 102 instead of the valve core, as shown in
The handle 118 can be atraumatic and ergonomic, for example, comprising an ellipsoid shape. Such a design can enhance comfort of a user wearing the handle 118 against the body. The shape of the handle 118 is also configured to blend into other components of the valve (e.g., valve core, cap, strain relief), which can help to minimize pinch points and enhance comfort.
The handle 118 can comprise a feature configured to interact with a component of the valve 110, which can serve to provide tactile user feedback of handle 118 position (e.g., closed position). The interaction can also encourage the handle 118 to stay in a closed position. For example, as shown in
As noted above, the handle 118 can comprise a feature configured to interact with the cover 114 to maintain the handle 118 in a particular position (e.g., a closed position). For example, as shown in
Moving to
The valve body 140 is positioned beneath the handle 118, as shown in
The valve body 140 comprises a flush hole 150 positioned between the first through hole 146 and the second through hole 148, as shown in
The flush hole 150 is shown positioned generally equidistant from through holes 146, 148. In some embodiments, the flush hole can be positioned closer to one of the through holes than the other. The flush hole 150 is shown positioned, in a vertical direction, generally centrally within the flow path. In other embodiments, the flush hole 150 can be positioned higher or lower than the position shown in
The flush hole 150 is a small hole with a diameter of about 0.050 inches. In some embodiments, the diameter of the flush hole 150 can be about 0.040-about 0.060 inches. The hole size can be selected to optimize flow through the hole 150. The flush hole 150 allows for the flushing of the dead volume within valve 110 and the solution set catheter. In some embodiments, the connector of the solution set catheter (e.g., Baxter UltraBag) may not be UV-transparent. In such embodiments, flushing any residual fluid away from the connector and out of the line can help promote thorough disinfection of the fluid line. The volume of fluid flushed can be selected based on the residual or dead volume within the solution set catheter and the valve. In some embodiments, the dead volume can be as low as about 0.3 cm3. In some embodiments, the dead volume is about 0.3 cm3-1 cm3. In some embodiments, the dead volume is about 0.3 cm3-0.6 cm3. In some embodiments, the dead volume is about 0.3 cm3-2 cm3. In some embodiments, the dead volume is about 1-2 cm3. In some embodiments, the dead volume can be less than or equal to about 2 cm3. In some embodiments, the volume flushed can be about 3 cm3 to allow for about a 10× margin of safety. Other volumes are also possible. For example, in some embodiments, the volume flushed can be about 1 cm3 to about 5 cm3; about 2 cm3 to about 4 cm3; greater than 5 cm3; etc.
The flush hole 150 can be used to flush fresh dialysate solution to the atmosphere instead of a separate drain container as the flush solution will comprise sterile dialysate. Any microorganisms within the dead volume are already present in the patient environment. As such, the flush solution can be safe to spill to the atmosphere. The flush solution can also be easy to clean after exiting the flush hole as only a small volume of solution is flushed. In some embodiments, the amount of fluid flushed can be caught in something as absorbent and small as a tissue.
The sidewalls 151 of the flush hole 150 can be tapered which can allow for molding. Tapering the walls of the flush hole 150 can also minimize parallel surfaces which are not optimized for UV disinfection as the UV light may be parallel to both surfaces. The wall edges can be sharp or rounded.
A valve core 142 is positioned within the valve body. The valve 110 allows fluid flow through the valve via a notch 144 or depression cut out of the valve core 142, as shown in
The valve core 142 can have a diameter of about 0.26 inches. In some embodiments, the diameter of the valve core 142 is about 0.2-0.3 inches.
The notch can be about 0.2 inches tall (direction along the height of the valve core 142). In some embodiments, the notch is about 0.15-0.25 inches tall. The notch can be about 0.2 inches deep (direction into interior of valve core 142). In some embodiments, the notch is about 0.15-0.25 inches deep. The notch can be about 0.26 inches wide (direction across valve core 142). In some embodiments, the notch is about 0.2-0.3 inches wide.
The flush hole 150 can be positioned in the valve body 140 so that it is at the approximate midpoint of the height of the notch 144, as shown in
In one aspect, the height of the notch 144 is about the same as the diameter of one or both of the through holes 146, 148. A circumference of the notch 144 can be the full size of the valve body 140 through holes 146, 148. Matching the size of the notch 144 and through holes 146, 148 can help eliminate choking of the flow and help prevent the through holes 146, 148 and/or notch 144 from getting plugged. A diameter of the through hole can be about 0.131 inches. In some embodiments, the diameter of the through hole is about 0.10-0.16 inches Providing for fluid flow through the valve 110 via a cut-out in the valve core instead of a through-hole in the valve core can allow for exteriorly applied UV light to disinfect the entire valve flow pathway, even if the valve core comprises non-UV transparent material. A valve core with a through-hole would not allow for fluid within a non-UV transmissive core to be disinfected. In some embodiments, the notch 144 has sharp edges, which can leave the maximum amount of surface area for valve core sealing.
Moving to
Additionally, a notch in the valve core reduces the surface area of the core available for sealing, for a given core diameter. A notch in a centered valve core would more greatly reduce the remaining valve core surface area available for sealing than a notch in an off-axis valve core, assuming the valve body size remains constant. A centered valve core with a notch would require a significantly larger valve body in order to maintain sufficient surface area for sealing various fluid paths. It can be important for the valve core to be able to seal off various flow paths to maintain the sterility of the various components.
An off-axis valve allows more degrees of rotation between the different valve positions. Requiring a user to rotate the valve a greater amount can help a user to select the right valve position. Ease in selecting the proper valve position can reduce user error in operating the valve.
As noted above, the off-axis nature of the valve can help allow for the valve to comprise a minimal volume. Minimizing the volume of the valve can minimize the volume to be disinfected. Minimizing the volume to be disinfected can minimize the amount of contaminants and, thus, the amount of UV required to disinfect. Thus, the UV can be on for less time and/or smaller or fewer bulbs can be used. If less power is required, fewer and/or smaller batteries can be used. Smaller power and/or UV sources can allow the enclosure to be smaller, which can increase comfort and convenience for the patient.
In some embodiments, the valve body 140 and valve core 142 can comprise different materials. For example, the valve core 142 can comprise molded-in seals in lower cost materials, commonly used for valve cores. Such materials can be softer than the UV transparent valve body. In some embodiments, the valve core 142 comprises or is coated with a UV reflective material, which can further optimize incident radiation on any volume to be disinfected.
The valve 110 can comprise a system to show a user the position of the valve. The system can comprise a dome 156 with an indicator positioned at the bottom of the valve core 142. In each valve position (flush, flow, and closed), the dome 156 aligns with symbols 168 on the valve body 140 that indicates the position of the valve 110. The indicator system is described in more detail below.
The valve 110 can comprise a key 154 positioned on the valve core 142, for example, at the bottom of the valve core as shown in
As stated above, the dome 156 can be positioned at the bottom of the valve core 142. The dome 156 can help to plug the bottom of the valve core 142, which can help eliminate the accumulation of nooks and crannies, minimizing the amount of contaminants in the valve 110. The dome 156 can have a slightly larger diameter than that of the valve core 142, which can help the dome 156 maintain its position within the core 142. The dome 156 can have a rounded shape, which can provide comfort to the patient while wearing the transfer catheter 100 in between dialysis sessions.
The dome 156 can include an indicator 158, for example, an embossed arrow as shown in
The valve 110 can be connected to the tubular body 102 via a connector, such as a barb 160 shown in
As noted above, the valve handle 118 can include a notch 126 positioned beneath the handle configured to interface with a trough 128, as shown in
In some embodiments, the tubular body 102, male luer 164, and cap 166 on the first end 104 of the transfer catheter 100, as shown in
The valve body 140 can include a feature 131 such as a rib, shown in
In use, when it is time for a dialysis session, a user begins with the transfer valve 110 in the closed position, as shown in the top view of
U.S. Provisional Patent Application No. 62/052,164, filed Sep. 18, 2014, the entire disclosure of which is hereby incorporated by reference herein, provides examples of UV light applicators. In some embodiments, the UV light applicator can comprise a box comprising a UV light source. The box comprises top and bottom halves hinged together. The box can be rectangular, square, ovular, etc. The box can be configured to be clamped over the connection between the transfer catheter and the solution set catheter. The box can include arcuate sections on each half that form apertures for the catheters when the catheters are positioned within the box. The box can be ambidextrous, meaning the box can be configured to receive the transfer catheter on the right side and the solution set catheter on the left side or vice versa. For example, in some embodiments, the solution set catheter connection may comprise a wide shoulder. The box can be configured to receive the shoulder, via a groove, on either the right or left side of the box.
The box can comprise a curved bottom surface shaped to contour to the thigh of a patient. The box can be sized to receive the transfer catheter disclosed herein. As described above, the transfer catheter can be designed to comprise a small kill zone. As such, the box may only comprise 4 UV lamps and 4 AA batteries as the power source. Such a box can be light enough to rest on the lap of a patient during disinfection or disinfection and dialysis.
Further embodiments of flushing in combination with UV disinfection of a catheter line connection are disclosed in U.S. Provisional Application No. 61/978,556 (the '556 application), filed on Apr. 11, 2014, entitled CONNECTOR DISINFECTION SYSTEM, the entire disclosure of which is incorporated herein by reference. In the '556 application, embodiments using non-gravity assisted flush are disclosed. For example, a syringe can be used to draw the flush out of PD fluid path. Embodiments disclosed herein relate to a gravity assisted flush, wherein a position of the dialysate bag causes the dialysate to be flushed to the atmosphere through the flush hole. It will be appreciated that any of the features or components of the '556 application can be used in combination with any of the features or components described herein. For example, a syringe or other non-gravity assist can be used to draw the flush out of the valve 110 described herein.
In still further embodiments, the size, shape, and included volume of the valves described herein are selected or optimized to reduce the volume of the valves (e.g., such as the valves described herein and in the '556 application or smaller). Reducing the volume of the valve can reduce the amount of UV used to disinfect and/or reduce the flush volume as the volume of potential contamination is reduced.
As noted above, it is believed that flushing in combination with UV sterilization can provide superior disinfection as compared to UV sterilization alone. PuraCath Medical and Phoenix deVentures performed a study a study comparing the effectiveness of flushing a PD fluid path with dialysate, exposing the path to UV light, or a combination of both. In the study, the inside fluid path of the Y-set connector and transfer catheter were inoculated with Staphylococcus aureus. After connecting the transfer catheter to the Y-set, the fluid path was either flushed with dialysate, exposed to UV light, or a combination of both methods.
The study showed a significant reduction in the growth of bacteria in the UV exposure+flush combination group vs. the UV exposure only group. The results indicate that combining a UV light delivery system with flushing, as in the embodiments disclosed herein, may permit a reduction in the risk of peritonitis in PD patients.
It will be appreciated that while the transfer catheter has been described in connection with peritoneal dialysis, the transfer catheter and/or valve can be used in numerous other applications, medical or otherwise such as with Central Venous Catheters (CVC) or Peripherally Inserted Central Catheter (PICC) either of which can be used for dialysis or other interventions.
Variations and modifications of the devices and methods disclosed herein will be readily apparent to persons skilled in the art. As such, it should be understood that the foregoing detailed description and the accompanying illustrations, are made for purposes of clarity and understanding, and are not intended to limit the scope of the invention, which is defined by the claims appended hereto. Any feature described in any one embodiment described herein can be combined with any other feature of any of the other embodiment whether preferred or not.
It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference for all purposes.
This application claims the benefit of U.S. Provisional Patent Application No. 62/008,433, filed Jun. 5, 2014.
Number | Name | Date | Kind |
---|---|---|---|
3517669 | Buono et al. | Jun 1970 | A |
3572375 | Rosenberg | Mar 1971 | A |
3626938 | Versaci | Dec 1971 | A |
3986508 | Barrington | Oct 1976 | A |
4146055 | Ryder | Mar 1979 | A |
4209013 | Alexander et al. | Jun 1980 | A |
4232428 | Johansson | Nov 1980 | A |
4242310 | Greff et al. | Dec 1980 | A |
4256135 | Hannah | Mar 1981 | A |
4336223 | Hillman | Jun 1982 | A |
4340052 | Dennehey et al. | Jul 1982 | A |
4346704 | Kulle | Aug 1982 | A |
4412834 | Kulin | Nov 1983 | A |
4433244 | Hogan | Feb 1984 | A |
4439188 | Dennehey et al. | Mar 1984 | A |
4440207 | Genatempo et al. | Apr 1984 | A |
4457794 | Kotera et al. | Jul 1984 | A |
4469835 | Laurin | Sep 1984 | A |
4473369 | Lueders et al. | Sep 1984 | A |
4475900 | Popovich et al. | Oct 1984 | A |
4500788 | Kulin et al. | Feb 1985 | A |
4541829 | Munsch et al. | Sep 1985 | A |
4573980 | Karrasch et al. | Mar 1986 | A |
4608472 | Kato | Aug 1986 | A |
4655762 | Rogers | Apr 1987 | A |
4745950 | Mathieu | May 1988 | A |
4774415 | Biegel et al. | Sep 1988 | A |
4877964 | Tanaka et al. | Oct 1989 | A |
4878516 | Mathieu | Nov 1989 | A |
4882496 | Bellotti et al. | Nov 1989 | A |
4948980 | Wedekamp | Aug 1990 | A |
4949723 | Wallace et al. | Aug 1990 | A |
4950230 | Kendell | Aug 1990 | A |
4950260 | Bonaldo | Aug 1990 | A |
4980374 | Steudle et al. | Dec 1990 | A |
5047011 | Caron et al. | Sep 1991 | A |
5057074 | Suzuki et al. | Oct 1991 | A |
5105853 | Lie | Apr 1992 | A |
5147321 | Slonina et al. | Sep 1992 | A |
5190534 | Kendell | Mar 1993 | A |
5221267 | Folden | Jun 1993 | A |
5242150 | Shiffler et al. | Sep 1993 | A |
5336173 | Folden | Aug 1994 | A |
5417673 | Gordon | May 1995 | A |
5427135 | Kieper | Jun 1995 | A |
5439451 | Collinson et al. | Aug 1995 | A |
5536258 | Folden | Jul 1996 | A |
5540668 | Wilson et al. | Jul 1996 | A |
5555908 | Edwards et al. | Sep 1996 | A |
5603902 | Maltais et al. | Feb 1997 | A |
5612001 | Matschke | Mar 1997 | A |
5640690 | Kudrna | Jun 1997 | A |
5713850 | Heilmann et al. | Feb 1998 | A |
5714119 | Kawagoe et al. | Feb 1998 | A |
5832959 | Szymczakowski | Nov 1998 | A |
5855203 | Matter | Jan 1999 | A |
6027489 | Galato | Feb 2000 | A |
6120166 | Price | Sep 2000 | A |
6228332 | Dunn et al. | May 2001 | B1 |
6245570 | Grimm et al. | Jun 2001 | B1 |
6418257 | Nath | Jul 2002 | B1 |
6461568 | Eckhardt | Oct 2002 | B1 |
6461569 | Boudreaux | Oct 2002 | B1 |
6470888 | Matter | Oct 2002 | B1 |
6485483 | Fujii | Nov 2002 | B1 |
6569564 | Lane | May 2003 | B1 |
6592558 | Quah | Jul 2003 | B2 |
6682507 | Irish | Jan 2004 | B2 |
6803363 | Polaschegg | Oct 2004 | B2 |
6834984 | Tausch et al. | Dec 2004 | B2 |
7083605 | Miyahara | Aug 2006 | B2 |
7198611 | Connell et al. | Apr 2007 | B2 |
7232428 | Inukai et al. | Jun 2007 | B1 |
7232429 | Moreci | Jun 2007 | B2 |
7274847 | Gowda et al. | Sep 2007 | B2 |
7452346 | Axelsson | Nov 2008 | B2 |
7497849 | Fangrow | Mar 2009 | B2 |
7806851 | Cerasoli | Oct 2010 | B2 |
7955295 | Lee et al. | Jun 2011 | B2 |
8197087 | Sobue et al. | Jun 2012 | B2 |
8282829 | Yu et al. | Oct 2012 | B2 |
8431074 | Neer | Apr 2013 | B2 |
8478385 | Liu et al. | Jul 2013 | B2 |
8585681 | Boenig et al. | Nov 2013 | B2 |
8641659 | Soykan et al. | Feb 2014 | B2 |
8946653 | Victor et al. | Feb 2015 | B2 |
20030010927 | Wedekamp | Jan 2003 | A1 |
20030017073 | Eckhardt et al. | Jan 2003 | A1 |
20040195538 | Raines et al. | Oct 2004 | A1 |
20050013729 | Brown-Skrobot et al. | Jan 2005 | A1 |
20050124970 | Kunin et al. | Jun 2005 | A1 |
20050163655 | Lin et al. | Jul 2005 | A1 |
20050258762 | Beland et al. | Nov 2005 | A1 |
20050261621 | Perez | Nov 2005 | A1 |
20060027270 | Truitt et al. | Feb 2006 | A1 |
20060122559 | Shia et al. | Jun 2006 | A1 |
20060147339 | Hunter et al. | Jul 2006 | A1 |
20060163515 | Ruschke | Jul 2006 | A1 |
20060186010 | Warnack et al. | Aug 2006 | A1 |
20070023710 | Tom et al. | Feb 2007 | A1 |
20070176117 | Redmond et al. | Aug 2007 | A1 |
20070179473 | Masters et al. | Aug 2007 | A1 |
20070232989 | Kitani et al. | Oct 2007 | A1 |
20070274879 | Millikin | Nov 2007 | A1 |
20070287953 | Ziv | Dec 2007 | A1 |
20080045884 | Landherr et al. | Feb 2008 | A1 |
20080183126 | Landherr et al. | Jul 2008 | A1 |
20080183127 | Landherr et al. | Jul 2008 | A1 |
20080195031 | Kitani et al. | Aug 2008 | A1 |
20080306454 | Sikora | Dec 2008 | A1 |
20090012451 | Sobue et al. | Jan 2009 | A1 |
20090149776 | Adams | Jun 2009 | A1 |
20090182309 | Muffly | Jul 2009 | A1 |
20090205664 | Lyon | Aug 2009 | A1 |
20090257910 | Segal | Oct 2009 | A1 |
20090259203 | Hu et al. | Oct 2009 | A1 |
20090289015 | Levy | Nov 2009 | A1 |
20090320316 | Zakai | Dec 2009 | A1 |
20100072399 | Street et al. | Mar 2010 | A1 |
20100072506 | Bae et al. | Mar 2010 | A1 |
20100249586 | Cocker et al. | Sep 2010 | A1 |
20110028915 | Slopes et al. | Feb 2011 | A1 |
20110064608 | Lee et al. | Mar 2011 | A1 |
20110085936 | Haytman et al. | Apr 2011 | A1 |
20110165020 | Tryggvason et al. | Jul 2011 | A1 |
20110213339 | Bak | Sep 2011 | A1 |
20110224624 | Geller | Sep 2011 | A1 |
20120053512 | Muse | Mar 2012 | A1 |
20120161032 | Arcand et al. | Jun 2012 | A1 |
20120205825 | Nagafuji et al. | Aug 2012 | A1 |
20120206992 | Stewart | Aug 2012 | A1 |
20120296151 | Curtis et al. | Nov 2012 | A1 |
20120310179 | Truitt et al. | Dec 2012 | A1 |
20120321509 | Bak | Dec 2012 | A1 |
20130131626 | Thompson | May 2013 | A1 |
20130204227 | Bochenko et al. | Aug 2013 | A1 |
20130303996 | Rasooly et al. | Nov 2013 | A1 |
20130323119 | Alwan | Dec 2013 | A1 |
20140076454 | Kjar | Mar 2014 | A1 |
20140205498 | Bak | Jul 2014 | A1 |
20140276215 | Nelson | Sep 2014 | A1 |
20140276345 | Silin | Sep 2014 | A1 |
20140334974 | Rasooly et al. | Nov 2014 | A1 |
20150258230 | Victor et al. | Sep 2015 | A1 |
Number | Date | Country |
---|---|---|
102536011 | Jul 2012 | CN |
103536443 | Jan 2014 | CN |
203408290 | Jan 2014 | CN |
0229786 | Mar 1990 | EP |
0163811 | Aug 1991 | EP |
2161040 | Mar 2010 | EP |
2314802 | Apr 2011 | EP |
2799373 | Apr 2001 | FR |
WO2016044821 | Mar 2016 | IN |
200868049 | Mar 2008 | JP |
WO8302060 | Jun 1983 | WO |
WO9219284 | Nov 1992 | WO |
WO02074350 | Sep 2002 | WO |
WO2007103998 | Sep 2007 | WO |
WO2008014437 | Jan 2008 | WO |
WO2009094034 | Jul 2009 | WO |
WO201100787 | Jan 2011 | WO |
WO2011143140 | Nov 2011 | WO |
WO2014013385 | Jan 2014 | WO |
WO2015157662 | Oct 2015 | WO |
Entry |
---|
Kermode et al.; U.S. Appl. No. 15/301,905 entitled “Connector disinfection system,” filed Oct. 4, 2016. |
Kermode et al.; U.S. Appl. No. 14/857,522 entitled “Ultraviolet disinfection unit,” filed Sep. 17, 2015. |
Lancer et al.; U.S. Appl. No. 15/074,854 entitled “Catheter connection system for ultraviolet light disinfection,” filed Mar. 18, 2016. |
Bak et al.; Disinfection of pseudomonas aeruginosa biofilm contaminated tube lumens with ultraviolet C light emitting diodes; Biofouling: The Journal of Bioadhesion and Biofilm Research; 26(1); pp. 31-38; Jan. 2010. |
Bak et al.; Dose requirement for UVC disinfection of catheter biofilms; Biofouling: The Journal of Bioadhesion and Biofilm Research; 25(3); pp. 289-296; Apr. 2009. |
Bak et al.; Potential in vivo UVC disinfection of catheter lumens: estimation of the doses received by the blood flow outside the catheter tip hole; Photochemistry and Photobiology; 87(2); pp. 350-356; Mar.-Apr. 2011. |
Bak et al.; UVC fluencies of preventative treatment of pseudomonas aeruginosa contaminated polymer tubes; Biofouling: The Journal of Bioadhesion and Biofilm Research; 26(7); pp. 821-828; Oct. 2010. |
Qamar et al; Clinical outcomes in peritoneal dialysis: Impact of continuous improvement quality initiatives; Advances in Peritoneal Dialysis; vol. 25; pp. 76-79; 2009 (year of pub. sufficiently earlier than effective US filing date and any foreign priority date). |
Number | Date | Country | |
---|---|---|---|
20150352348 A1 | Dec 2015 | US |
Number | Date | Country | |
---|---|---|---|
62008433 | Jun 2014 | US |